


Supplementary material 3:


The network of eligible comparisons

ARI: aripiprazole, BLO: blonanserin, CLO: clozapine, Cloca: clocapramine, HAL: haloperidol, MOS: mosapramine, OLA: olanzapine, PAL: paliperidone, PER: perospirone, PBO: placebo, QUE: quetiapine, RIS: risperidone


PANSS total scores




Response rate (primary outcome for efficacy)




PANSS positive subscale scores




PANSS negative subscale scores




All-cause discontinuation (primary outcome for acceptability)




PANSS general subscale scores




Discontinuation due to adverse events




At least one adverse event




Insomnia/use of hypnotics




Agitation/anxiety/use of anxiolytics




Drowsiness/sedation/somnolence




Extrapyramidal symptoms/use of anticholinergic drugs/tremor




Increased salivation




Akathisia




Potentially prolactin-related adverse events



Weight change



Triglyceride



Total cholesterol

